Pathology
病理
基本信息
- 批准号:6986013
- 负责人:
- 金额:$ 20.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Epigenetic silencing of critical genes through aberrant methylation appears to play a key role in tumor
development. To advance our basic understanding of the epigenetic regulation of gene expression in cancer
cells, and clinically test the hypothesis that remethylation of genes has therapeutic potential, we will
investigate chronic lymphocytic leukemia (CLL) as a model in the projects presented in this program project
proposal. However, the ability to meaningfully conduct basic studies and translate important findings to the
clinical setting is greatly facilitated by the availability of an extensive repository of tissue samples, with
accompanying pathologic and clinical data, procured from relevant patients CLL. This Core, the
Pathology/Tissue Procurement Core, through the collaboration of the OSU Leukemia Tissue Bank (LTB),
will serve this function in supporting the basic and clinical projects of this Program Project. The OSU leukemia
tissue bank has a well-established infrastructure directly under our leadership. The Core will participate in the
procurement of procurement of CLL cells and the molecular characterization of CLL cases for the Projects. All
the essentials of effective tissue bank management, including the activities of tissue collection, quality control
of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical
information, data entry and database management, and patient consent and confidentiality are very well
developed in this Core. In addition, this Core has the established capacity to process procured specimens for
the preparation of pure cell populations (e.g., CLL cells though CD19 positive selection), cell lysates, nucleic
acids and proteins in a uniform manner for ready distribution to investigators. Furthermore, the procedures for
prioritizing and distributing tissue to a large base of investigators, within and outside our institution, are
effectively in place. Against this background, we believe that this Core will function well in the support of the
5 projects proposed in this application, as well as future projects and collaborations. While funding currently
exists for the infrastructure of OSU LTB, it is emphasized that there is no overlap in funding requested for this
Core, as all of the new work proposed in this Program Project is not currently funded by NCI or other peer
reviewed grants. The Specific Aims of this Core are, therefore, to: 1) provide central collection, processing
and a state-of-the-art repository for samples collected from CLL patients treated at OSU, including protocols
relevant to this Program Project; 2) provide materials from processed CLL samples for the support of Projects
1-5 of this Program Project proposal in a standardized manner, and 3) perform molecular characterization,
including cytogenetic fluorescent in-situ hybridization (FISH) studies, lgVH and p53 mutational status, on all
CLL cases used in the Projects to permit subsequent correlation with clinical and laboratory results.
通过异常甲基化导致的关键基因的表观遗传沉默似乎在肿瘤中起着关键作用
发展促进我们对癌症基因表达的表观遗传调控的基本理解
细胞,并在临床上测试基因再甲基化具有治疗潜力的假设,我们将
研究慢性淋巴细胞白血病(CLL)作为本项目中提出的项目的模型
提议然而,有意义地进行基础研究并将重要发现转化为
由于可获得广泛的组织样本储存库,
附病理和临床数据,从相关患者CLL获得。这个核心,
病理学/组织采购核心,通过OSU白血病组织库(LTB)的合作,
将在支持本计划项目的基础和临床项目中发挥这一作用。OSU白血病
组织库有一个完善的基础设施,直接在我们的领导下。核心将参加
为项目采购CLL细胞和CLL病例的分子表征。所有
有效组织库管理的要素,包括组织采集、质量控制
标本、组织储存、初始和随访样本的获取及其病理学和临床
信息、数据输入和数据库管理以及患者同意和保密性都非常好
在这个核心中发展。此外,该中心还具备处理采购标本的既定能力,
纯细胞群的制备(例如,CLL细胞通过CD 19阳性选择),细胞裂解物,核酸
酸和蛋白质以统一的方式准备分发给研究人员。此外,
优先考虑和分发组织给我们机构内外的大量研究人员,
有效到位。在这一背景下,我们认为,这一核心将在支持联合国
本申请中提出的5个项目,以及未来的项目和合作。虽然目前资金
OSU LTB的基础设施存在,需要强调的是,
核心,因为本计划项目中提出的所有新工作目前都没有得到NCI或其他同行的资助
审查赠款。因此,本核心的具体目标是:1)提供中央收集、处理
和一个最先进的储存库,用于收集在俄勒冈州立大学治疗的CLL患者的样本,包括方案
与本计划项目相关; 2)提供来自已处理CLL样品的材料,以支持项目
1-5以标准化的方式,和3)进行分子表征,
包括细胞遗传学荧光原位杂交(FISH)研究、lgVH和p53突变状态,
项目中使用的慢性淋巴细胞白血病病例,以便随后与临床和实验室结果相关联。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sherif S Farag其他文献
The emin Vitro/em and emIn Vivo/em Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention
- DOI:
10.1182/blood-2022-163679 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:23.100
- 作者:
Shuhong Zhang;Xingkui Xue;Maggie Granatir;George E. Sandusky;Sheng Liu;Jun Wan;Xiaoling Xuei;Yunlong Liu;Anthony L. Sinn;Karen E. Pollok;Sherif S Farag - 通讯作者:
Sherif S Farag
The <em>in Vitro</em> and <em>In Vivo</em> Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention
- DOI:
10.1182/blood-2022-163679 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Shuhong Zhang;Xingkui Xue;Maggie Granatir;George E. Sandusky;Sheng Liu;Jun Wan;Xiaoling Xuei;Yunlong Liu;Anthony L. Sinn;Karen E. Pollok;Sherif S Farag - 通讯作者:
Sherif S Farag
Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
- DOI:
10.1182/blood-2022-162406 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Peter Westervelt;Partow Kebriaei;Mark Juckett;Andrew S. Artz;Onyee Chan;Philip L. McCarthy;Sherif S Farag;Anurag K. Singh;Eytan Stein;Jeffrey Humphrey;William Baeder;Ji Hyun Lee;Alison Occhiuti;Jeanie Tang;David Santos;Kirk Bertelsen;Balaji Mahender;Nicole Henry;Shawn Rose - 通讯作者:
Shawn Rose
The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
- DOI:
10.1182/blood-2022-167619 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Mohammad Issam Abu Zaid;Parvathi Sudha;Travis S Johnson;Vivek S. Chopra;Cedric E. Dos Santos;Michael Nixon;Attaya Suvannasankha;Sherif S Farag;Kelvin P. Lee;Rafat Abonour;Brian A. Walker - 通讯作者:
Brian A. Walker
Sherif S Farag的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sherif S Farag', 18)}}的其他基金
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells
抑制 PGE2 对自体外周血干细胞动员的影响
- 批准号:
9261489 - 财政年份:2014
- 资助金额:
$ 20.85万 - 项目类别:
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells
抑制 PGE2 对自体外周血干细胞动员的影响
- 批准号:
8633799 - 财政年份:2014
- 资助金额:
$ 20.85万 - 项目类别:
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells
抑制 PGE2 对自体外周血干细胞动员的影响
- 批准号:
9052158 - 财政年份:2014
- 资助金额:
$ 20.85万 - 项目类别:
Multiple kinase target inhibition with EMND-2076 in multiple myeloma
EMND-2076 对多发性骨髓瘤的多激酶靶点抑制
- 批准号:
8013948 - 财政年份:2010
- 资助金额:
$ 20.85万 - 项目类别:
Multiple kinase target inhibition with EMND-2076 in multiple myeloma
EMND-2076 对多发性骨髓瘤的多激酶靶点抑制
- 批准号:
7787139 - 财政年份:2010
- 资助金额:
$ 20.85万 - 项目类别:
QMS Technology to Deplete T Cell Alloreactivity
QMS 技术消除 T 细胞同种异体反应性
- 批准号:
6891062 - 财政年份:2004
- 资助金额:
$ 20.85万 - 项目类别:
mTOR Inhibition as a Therapeutic Target in Myeloma
mTOR 抑制作为骨髓瘤的治疗靶点
- 批准号:
6940691 - 财政年份:2004
- 资助金额:
$ 20.85万 - 项目类别:
mTOR Inhibition as a Therapeutic Target in Myeloma
mTOR 抑制作为骨髓瘤的治疗靶点
- 批准号:
6887130 - 财政年份:2004
- 资助金额:
$ 20.85万 - 项目类别:
QMS Technology to Deplete T Cell Alloreactivity
QMS 技术消除 T 细胞同种异体反应性
- 批准号:
7460784 - 财政年份:2004
- 资助金额:
$ 20.85万 - 项目类别:
相似国自然基金
精神分裂症脑网络异常的影像遗传学研究
- 批准号:81000582
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
孤独症全基因组关联第二阶段研究
- 批准号:81071110
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
孤独症与突触发育相关候选基因的关联研究
- 批准号:30870897
- 批准年份:2008
- 资助金额:50.0 万元
- 项目类别:面上项目
用dsDNA微阵列筛选NF-κB DNA靶点及靶基因
- 批准号:60871014
- 批准年份:2008
- 资助金额:35.0 万元
- 项目类别:面上项目
大鱼际掌纹特应征与5个哮喘易感基因单核苷酸多态性的关联分析
- 批准号:30873315
- 批准年份:2008
- 资助金额:31.0 万元
- 项目类别:面上项目
相似海外基金
Integrin alpha6beta4 regulation of cancer epigenetics
整合素α6β4对癌症表观遗传学的调节
- 批准号:
10551214 - 财政年份:2019
- 资助金额:
$ 20.85万 - 项目类别:
Integrin alpha6beta4 regulation of cancer epigenetics
整合素α6β4对癌症表观遗传学的调节
- 批准号:
10321610 - 财政年份:2019
- 资助金额:
$ 20.85万 - 项目类别:
Childhood adversity, DNA methylation, and psychopathology symptoms: A longitudinal study of sensitive periods and chrono-epigenetics
童年逆境、DNA 甲基化和精神病理学症状:敏感期和时间表观遗传学的纵向研究
- 批准号:
10444309 - 财政年份:2017
- 资助金额:
$ 20.85万 - 项目类别:
Splicing and Epigenetics Regulation of Hematopoietic Stem Cells
造血干细胞的剪接和表观遗传学调控
- 批准号:
8769909 - 财政年份:2014
- 资助金额:
$ 20.85万 - 项目类别:
Subnuclear Targeting and Architectural Epigenetics in Cancer Cells
癌细胞的亚核靶向和结构表观遗传学
- 批准号:
8601045 - 财政年份:2013
- 资助金额:
$ 20.85万 - 项目类别: